Table 4.

Impact of study characteristics to the effects of atorvastatin therapy on serum adiponectin concentrations: results of subgroup analyses

Study characteristics	WMD of serum adiponectin concentration (ug/ml)
	Comparisons (patients), n	I2	WMD [95% CI]	p1	p2
R, DB, PC studies
Yes	4 (396)	73%	− 1.02 [−2.27, 0.22]	0.11
No	10 (535)	50%	0.06 [−0.64, 0.77]	0.86	0.14
Crossover studies
Yes	2 (196)	0%	−0.13 [− 0.72, 0.46]	0.66
No	12 (735)	65%	−0.33 [−1.13, 0.47]	0.42	0.70
Patients with DM
Yes	5 (396)	59%	−0.95 [−2.18, 0.29]	0.13
No	9 (535)	57%	0.03 [−0.65, 0.71]	0.96	0.18
Patients with dyslipidemia
Yes	7 (398)	0%	−0.28 [−0.75, 0.19]	0.24
No	7 (533)	79%	−0.42 [−1.71, 0.87]	0.52	0.84
Mean age
≤ 56 years	7 (419)	80%	0.02 [−1.13, 1.18]	0.97
> 56 years	7 (512)	0%	−0.54 [−1.13, 0.04]	0.07	0.39
Male
≤ 52%	8 (499)	56%	0.09 [−0.63, 0.81]	0.81
> 52%	6 (432)	65%	−0.88 [−2.02, 0.27]	0.13	0.16
BMI
≤ 26 kg/m2	9 (535)	57%	0.03 [−0.65, 0.71]	0.94
> 26 kg/m2	5 (396)	59%	−0.95 [−2.18, 0.29]	0.13	0.18
Dose
10 mg	6 (407)	12%	−0.32 [− 0.92, 0.28]	0.29
20 mg	3 (206)	84%	−1.15 [−3.11, 0.81]	0.25
40 mg	3 (159)	75%	0.67 [−1.18, 2.51]	0.84
80 mg	2 (159)	0%	−0.35 [−1.42, 0.71]	0.52	0.62
Follow-up duration
≤ 8 weeks	8 (520)	0%	−0.19 [− 0.62, 0.24]	0.40
> 8 weeks	6 (411)	82%	−0.59 [−2.20, 1.02]	0.47	0.64
Adiponectin assay
ELISA	11 (720)	38%	−0.01 [− 0.57, 0.54]	0.96
RIA	3 (211)	85%	−1.48 [−3.74, 0.79]	0.20	0.22

Abbreviations: WMD weighed mean difference, CI confidence interval, R random, DB double-blinded, PC placebo-controlled, BMI body mass index, ELISA enzyme-linked immunosorbent assay, RIA radioimmunoassay

¹p values for subgroup effects

²p values for subgroup interaction